InMed Pharmaceuticals News

Press Releases

InMed Pharmaceuticals to Report Fourth Quarter, and Full Year Fiscal 2019 Financial Results and Business Update on September 19, 2019

September 12, 2019

InMed Pharmaceuticals to Present at the H.C. Wainwright 21st Annual Global Investment Conference

September 3, 2019

InMed Pharmaceuticals to Attend the 2nd Annual International Cannabinoid-Derived Pharmaceuticals Summit

August 29, 2019

InMed Pharmaceuticals Appoints Bruce S. Colwill, CPA, CA as Chief Financial Officer and Announces other Leadership Changes

August 2, 2019

InMed Pharmaceuticals Appoints Catherine Sazdanoff to Board of Directors

July 2, 2019

InMed Pharmaceuticals Reports Third Quarter Fiscal 2019 Financial Results and Provides R&D and Business Update

May 15, 2019

InMed Pharmaceuticals to Report Third Quarter Fiscal 2019 Financial Results and Business Update on May 15, 2019

May 8, 2019

InMed Continues to Strengthen IP Portfolio for its Biosynthesis Platform Technology

March 18, 2019

InMed Pharmaceuticals Announces Transition to a Single Cannabinoid Investigational Drug Candidate – INM-755 – for its Epidermolysis Bullosa Program

March 13, 2019

InMed Pharmaceuticals to Present at the 31st Annual ROTH Conference on March 19, 2019

March 12, 2019

InMed Pharmaceuticals Appoints Dr. Steven M. Dinh to Scientific Advisory Board

March 6, 2019

InMed Pharmaceuticals Reports Second Quarter Fiscal 2019 Financial Results and Provides R&D and Business Update

February 12, 2019

InMed Pharmaceuticals to Report Second Quarter Fiscal 2019 Financial Results and Business Update on February 12, 2019

February 5, 2019

InMed Pharmaceuticals Announces the Appointment of Dr. Sazzad Hossain, PhD, MSc, as a Member of the Scientific Advisory Board and his Retirement as Chief Scientific Officer

January 11, 2019

InMed Pharmaceuticals to Present at Biotech Showcase 2019 on January 9, 2019

January 3, 2019

InMed Pharmaceuticals Receives Funding from the Government of Canada to Support Development of Novel Cannabinoid Biosynthesis Program

December 4, 2018

InMed Pharmaceuticals Reports First Quarter Fiscal 2019 Financial Results and Provides R&D and Business Update

November 12, 2018

InMed Pharmaceuticals to Report First Quarter Fiscal 2019 Financial Results and Business Update on November 12, 2018

November 5, 2018

InMed Pharmaceuticals Appoints Michael Woudenberg as Vice President, Chemistry, Manufacturing, and Controls

November 5, 2018

InMed Pharmaceuticals to Present at BIO Investor Forum on October 17, 2018

October 10, 2018

Management

Learn More

Board of Directors

Learn More

Scientific Advisory Board

Learn More

Press Releases

InMed Pharmaceuticals to Report Fourth Quarter, and Full Year Fiscal 2019 Financial Results and Business Update on September 19, 2019

InMed Pharmaceuticals to Present at the H.C. Wainwright 21st Annual Global Investment Conference

InMed Pharmaceuticals to Attend the 2nd Annual International Cannabinoid-Derived Pharmaceuticals Summit

InMed Pharmaceuticals Appoints Bruce S. Colwill, CPA, CA as Chief Financial Officer and Announces other Leadership Changes

InMed Pharmaceuticals Appoints Catherine Sazdanoff to Board of Directors

InMed Pharmaceuticals Reports Third Quarter Fiscal 2019 Financial Results and Provides R&D and Business Update

InMed Pharmaceuticals to Report Third Quarter Fiscal 2019 Financial Results and Business Update on May 15, 2019

InMed Continues to Strengthen IP Portfolio for its Biosynthesis Platform Technology

InMed Pharmaceuticals Announces Transition to a Single Cannabinoid Investigational Drug Candidate – INM-755 – for its Epidermolysis Bullosa Program

InMed Pharmaceuticals to Present at the 31st Annual ROTH Conference on March 19, 2019

InMed Pharmaceuticals Appoints Dr. Steven M. Dinh to Scientific Advisory Board

InMed Pharmaceuticals Reports Second Quarter Fiscal 2019 Financial Results and Provides R&D and Business Update

InMed Pharmaceuticals to Report Second Quarter Fiscal 2019 Financial Results and Business Update on February 12, 2019

InMed Pharmaceuticals Announces the Appointment of Dr. Sazzad Hossain, PhD, MSc, as a Member of the Scientific Advisory Board and his Retirement as Chief Scientific Officer

InMed Pharmaceuticals to Present at Biotech Showcase 2019 on January 9, 2019

InMed Pharmaceuticals Receives Funding from the Government of Canada to Support Development of Novel Cannabinoid Biosynthesis Program

InMed Pharmaceuticals Reports First Quarter Fiscal 2019 Financial Results and Provides R&D and Business Update

InMed Pharmaceuticals to Report First Quarter Fiscal 2019 Financial Results and Business Update on November 12, 2018

InMed Pharmaceuticals Appoints Michael Woudenberg as Vice President, Chemistry, Manufacturing, and Controls

InMed Pharmaceuticals to Present at BIO Investor Forum on October 17, 2018

Management

Board of Directors

Scientific Advisory Board

Investor Alerts

Sign up to receive emails from InMed Pharmaceuticals